New triple-drug attack aims to wipe out aggressive breast cancer before surgery

NCT ID NCT07351487

Recruiting now Disease control Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jan 23, 2026 · Last updated May 09, 2026 · Updated 16 times

Summary

This study tests whether adding two targeted drugs (sintilimab and bevacizumab) to standard chemotherapy before surgery can completely eliminate triple-negative breast cancer in 37 women with stage II-III disease. The main goal is to see how many patients have no cancer left in the removed tissue. The approach aims to control the disease and improve long-term outcomes, but ongoing management may still be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The First Affiliated Hospital of Anhui Medical University
RECRUITING

Hefei, China

Contact
Zhongshan Hospital, Fudan University
RECRUITING

Shanghai, China

Contact

Conditions

Explore the condition pages connected to this study.

TNBC, TRIPLE NEGATIVE BREAST CANCER